

12 **Supplementary Materials and Methods**

13

14 ***Preparation of peanut protein***

15 Crude peanut extract (PE) was prepared from defatted raw flours (Golden Peanut
16 Company, Alpharetta, GA) as previously described (E1). Briefly, the flour (1:10, wt/vol) was
17 extracted in 10x PBS overnight at 4°C. After centrifugation at 30,000g for 60 minutes, the
18 supernatant was filter-sterilized, measured for protein concentration using the BCA method
19 (Pierce, Rockford, IL), and stored as aliquots at -20°C. Endotoxin levels in PE solutions were
20 less than 0.1 EU/ml as assessed by a Chromogenic LAL endotoxin assay kit (GeneScript,
21 Piscataway, NJ).

22

23 ***Sensitization and intragastric challenge***

24 The experimental protocol for sensitization and challenge to peanut was previously
25 described (17). Briefly, mice were sensitized 3 times with 500 µg of PE together with 2.0 mg of
26 alum (Pierce, Rockford, IL) by means of intraperitoneal injection in a total volume of 100 mL on
27 days 1, 7, and 21. Two weeks later, mice received 20 mg of PE (in 250 mL of PBS) by means of
28 gavage with a 22-gauge feeding needle (Fisher Scientific, Pittsburgh, PA) every day for 1 week.
29 Thirty minutes after the last challenge, plasma was collected and stored at -80°C. Twenty-four
30 hours after the last challenge, mice were killed. Serum and jejunal tissue were collected for
31 further analyses. Control animals were sham sensitized but challenged with peanut.

32

33

34

35 ***Cyp11a1 inhibitor and treatment***

36 AMG was dissolved in 1 M hydrogen chloride and diluted with saline for in vivo studies
37 or diluted with RPMI medium for in vitro study. The final concentration of 1 M hydrogen
38 chloride was less than 1% and 0.05% for in vivo and in vitro, respectively. PE sensitized and
39 challenged mice received different doses (5, 10, 20 mg/kg) of the Cyp11a1 enzyme inhibitor
40 (PE/PE/AMG) by means of gavage using a 22-gauge feeding needle (Fisher Scientific) twice a
41 day during the peanut challenge phase. Controls included PE sensitized and challenged but
42 vehicle (saline) treated (PE/PE/vehicle), or sham sensitized but PE challenged and vehicle-
43 treated (PBS/PE/vehicle) mice.

44

45 ***Histology***

46 Jejunum was fixed in 10% formalin and processed into paraffin blocks. Five-micrometer-
47 thick tissue sections were cut and stained with periodic acid-Schiff for detection of mucus-
48 containing cells (20). The number of mucus-containing cells from one side of the villus and the
49 total number of villus cells on the same side were counted. The number of mucus-containing
50 cells was expressed as the percentage of mucus-containing cells divided by the total number of
51 cells counted. At least 10 randomly selected villi were counted on each slide.

52

53 ***Assessment of hypersensitivity reactions***

54 Anaphylactic symptoms were evaluated 30 minutes after the oral challenge, as previously
55 reported (E2). Briefly, 0: no symptoms; 1: scratching and rubbing around the nose and head; 2:
56 puffiness around the eyes and mouth, diarrhea, pilar erecti, reduced activity, and/or decreased
57 activity with increased respiratory rate; 3: wheezing, labored respiration, and cyanosis around the

58 mouth and the tail; 4: no activity after prodding or tremor and convulsion; and 5: death. Scoring
59 of symptoms was performed in a blinded manner by an independent observer.

60

61 ***Measurement of peanut-specific antibody***

62 Serum peanut-specific IgE, IgG1, and IgG2a levels were measured by ELISA, as described
63 previously (19, 21). Briefly, Immulon II 96-well plates (Dynatech Laboratories, Chantilly, VA)
64 were coated with 2 µg/mL PE in coating buffer (eBioscience). Detection was performed with
65 horse-radish peroxidase-conjugated goat anti-mouse IgG1 and IgG2a (SouthernBiotech,
66 Birmingham, AL) and biotin rat anti-mouse IgE (BD Pharmingen, Franklin Lakes, NJ),
67 respectively. The peroxidase activity was measured with tetramethylbenzidine (eBioscience) at
68 450 nm.

69

70 ***Histamine levels in plasma***

71 Levels of histamine in plasma were measured using an enzyme immunoassay histamine
72 kit (Beckman Coulter, Fullerton, CA), as described by the manufacturer. The concentration of
73 histamine was calculated from a standard curve provided by the manufacturer.

74

75 ***T-cell differentiation and treatment with the Cyp11a1 inhibitor in vitro***

76 Differentiation of Th1, Th2, or Th17 cells was performed as previously described with
77 minor changes (E3, E4). CD4⁺CD45RB⁺ T cells were isolated from naive TCR-transgenic mice
78 (OT II mice) spleen using a cell sorter (MoFlo XDP, Beckman Coulter). In the presence of
79 mitomycin-C-treated spleen cells, 5 µg/ml OVA₃₂₃₋₃₃₉ peptide, and the inhibitor AMG (400 µM),
80 isolated naive CD4 T cells were cultured with rmIL-2 (10 ng/ml, R/D Systems), rmIL-12 (10

81 ng/ml, Peprotech), rmIFN- γ (5 ng/ml, Peprotech), and anti-IL-4 mAbs (10 μ g/ml, eBioscience)
82 to induce Th1 cell differentiation; with rmIL-2 (10 ng/ml, R/D Systems), rmIL-4 (5 ng/ml,
83 Peprotech), and anti-IFN- γ mAb (10 μ g/ml, eBioscience) for differentiation of Th2 cells; and
84 with rhIL-6 (50 ng/ml, Perotech), rhTGF- β (2 ng/ml, Peprotech), rmIL-23 (10 ng/ml, Peprotech),
85 anti-IL-4 mAb (10 μ g/ml, eBioscience), and anti-IFN- γ mAb (10 μ g/ml, eBioscience) for
86 differentiation of Th17 cells. After 6 days of culture, the cells were washed with fresh medium
87 and restimulated with anti-CD3/anti-CD28 for 24 hrs for assay of cytokine production. The cells
88 were collected for quantitative RT-PCR and Western blot. For transduction experiments, the
89 cells were cultured under Th1, Th2, and Th17 polarizing conditions for 5 days as described in
90 Methods.

91

92 ***Western blot analysis***

93 Cultured cells were lysed as previously described (E5). Lysates were resolved by means
94 of SDS-PAGE and transferred to nitrocellulose membranes. Proteins were detected using
95 antibodies specific for Cyp11a1 (LifeSpan Biosciences, Seattle, WA) followed by
96 chemiluminescence detection (GE Healthcare, Little Chalfont, UK).

97

98

99 ***Quantitative real-time PCR***

100 RNA was extracted from jejunal tissue homogenates or from CD4 T cells cultured in
101 vitro using Trizol (Invitrogen). cDNA was generated using the iScript cDNA synthesis kit (Bio-
102 Rad Laboratories, Hercules, CA). Quantitative RT-PCR was performed on the ABI Prism 7300
103 sequence detection system (Applied Biosystems, Foster City, CA). All primers and probes used

104 were purchased as Tagman Gene Expression Assays from Applied Biosystems. Fold change was
105 calculated using the Delta Delta cycle threshold ($\Delta\Delta C_T$) method.

106

107 ***Expression constructs***

108 The *Cyp11a1* short hairpin RNA (shRNA) sequence was generated using the Dharmacon
109 siDESIGN center (Thermo Scientific) web site
110 (<http://www.dharmacon.com/designcenter/designcenterpage.aspx>) and are described in the
111 Online Supplement. *Cyp11a1* sense 5'-
112 TTCAATAAAGCTGATGAGTATTCAAGAGATACTCATCAGCTTTATTGATTTTTTC-3',
113 anti-sense 5'-
114 TCGAGAAAAAATCAATAAAGCTGATGAGTATCTCTTGAATACTCATCAGCTTTATTG
115 AA-3'. Control firefly *luciferase (luc)* shRNA was described previously (25). To construct the
116 shRNA expression vectors, PAGE-purified and phosphorylated oligonucleotides (Integrated
117 DNA Technologies, Coralville, IA) encoding *Cyp11a1* shRNA were annealed and ligated into a
118 modified pQCXIP vector (Clontech, Mountain View, CA) expressing cyan fluorescent protein
119 (CFP) (25). Plasmid DNA encoding mouse *Cyp11a1* and control firefly *luc* were purified using
120 endofree plasmid maxi kit (Qiagen, Valencia, CA) and sequenced (Eton Bioscience, San Diego,
121 CA).

122

123 ***Retrovirus production and transduction***

124 Retrovirus production was performed as previously described (26). Phoenix (Φ NX)
125 packaging cells were plated on poly-d-lysine-coated 100-mm dishes and cultured overnight to
126 reach 60 to 80% confluency. Cells were co-transfected with the pCL-Eco viral packaging

127 plasmid and plasmid DNA encoding *Cyp11a1*, or control *luc* shRNA using Lipofectamine 2000
128 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Two days post-
129 transfection, the virus-containing supernatant was collected and used to transfect cells.

130 Retroviral transduction of Th2 cells was performed as previously described (27). Sorted
131 CD4⁺ T cells were cultured under Th2 cell differentiation conditions as previously reported (24).
132 Cells were transduced with retroviruses (control *luc* shRNA or *Cyp11a1* shRNA) by
133 centrifugation in the presence of 8 µg/ml polybrene (Sigma). Cells were expanded and analyzed
134 on day 5.

135

136 **Supplementary Figure Legends**

137 **Figure E1.** Decreased mast cell infiltration in the intestinal wall of PE/PE mice treated with
138 AMG. Intestinal mucosa mast cells were quantified in jejunum using chloroacetate esterase
139 staining. Representative sections of (A) PBS/PE/vehicle mice; (B) PE/PE/vehicle mice; (C)
140 PE/PE/AMG (5 mg/kg) mice; (D) PE/PE/AMG (10 mg/kg) mice; and (E) PE/PE/AMG (20
141 mg/kg) mice. Magnification x400. Bar=100 μ M.

142

143 **Figure E2.** Decreased numbers of goblet cells in intestinal epithelium of sensitized and
144 challenged mice treated with AMG. Goblet cells were identified by PAS staining 24 hrs after the
145 last challenge. Representative sections of (A) PBS/PE/vehicle mice, (B) PE/PE/vehicle mice, (C)
146 PE/PE/AMG (5 mg/kg) mice, (D) PE/PE/AMG (10 mg/kg) mice, and (E) PE/PE/AMG (20
147 mg/kg) mice. Magnification x200. Bar=100 μ M.

148

149 **Figure E3.** Treatment with AMG had no effect on serum immunoglobulin production in peanut
150 sensitized and challenged mice. Serum levels of peanut-specific IgE, IgG1, and IgG2a were
151 assessed by ELISA 24 hrs after the last challenge and expressed as optical density of diluted
152 serum as described in Methods. Results were obtained from 3 individual experiments with 4
153 mice per group. #P<0.001, n.s. not significant.

154

155 **Figure E4.** Treatment with AMG had no effect on plasma estradiol production in peanut
156 sensitized and challenged mice. Plasma levels of estradiol were assessed by ELISA 30 minutes
157 after the last challenge. Results were obtained from 3 individual experiments with 4 mice per
158 group. n.s.: not significant.

159

160 **Figure E5.** Dose-dependent inhibitory effects of AMG on cytokine production in *in vitro*
161 polarized Th cells. Cytokine levels in supernatants of cultured CD4 T cells treated with different
162 doses of the inhibitor or vehicle under Th1, Th2, and Th17 polarizing conditions. *P<0.05, n.s.:
163 not significant.

164

165 **Figure E6.** Cell viability in the presence of different concentrations of AMG in *in vitro* cultures
166 of polarized Th cells. Results were obtained from 3 individual experiments. *P<0.05.

167

168

169 **References**

170

171 E1. Wang M, Takeda K, Shiraishi Y, Okamoto M, Dakhama A, Joetham A, et al. Peanut-induced
172 intestinal allergy is mediated through a mast cell-IgE-FcepsilonRI-IL-13 pathway. *J Allergy Clin*
173 *Immunol* 2010;126:306-16.

174

175 E2. Li XM, Serebrisky D, Lee SY, Huang CK, Bardina L, Schofield BH. A murine model of
176 peanut anaphylaxis: T- and B-cell responses to a major peanut allergen mimic human responses.
177 *J Allergy Clin Immunol* 2000;106:150-8.

178

179 E3. Ashino S, Wakita D, Shiohama Y, Iwakura Y, Chamoto K, Ohkuri T, et al. A T(h)17-
180 polarized cell population that has infiltrated the lung requires cells that convert to IFN- γ
181 production in order to induce airway hyperresponsiveness. *Intl Immunol* 2010;22:503-13.

182

183 E4. Komine O, Hayashi K, Natsume W, Watanabe T, Seki Y, Seki N, et al. The Runx1
184 transcription factor inhibits the differentiation of naive CD4⁺ T cells into the Th2 lineage by
185 repressing GATA3 expression. *J Exp Med* 2003;198:51-61.

186

187 E5. Ohnishi H, Miyahara N, Dakhama A, Takeda K, Mathis S, Haribabu B, et al. Corticosteroids
188 enhance CD8⁺ T cell-mediated airway hyperresponsiveness and allergic inflammation by
189 upregulating leukotriene B4 receptor 1. *J Allergy Clin Immunol* 2008;121:864-71.

Figure E1




Figure E2




Figure E3




Figure E4




Figure E5




Figure E6

